tetano
Editor, Senior Moderator
Vaccines (Basel). 2018 Aug 30;6(3). pii: E58. doi: 10.3390/vaccines6030058.
[h=1]The Future of Influenza Vaccines: A Historical and Clinical Perspective.[/h] Bouvier NM[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] For centuries, the development of vaccines to prevent infectious disease was an empirical process. From smallpox variolation in Song dynasty China, through the polysaccharide capsule vaccines developed in the 1970s, vaccines were made either from the pathogen itself, treated in some way to render it attenuated or non-infectious, or from a closely related non-pathogenic strain. In recent decades, new scientific knowledge and technologies have enabled rational vaccine design in a way that was unimaginable before. However, vaccines optimal against some infectious diseases, influenza among them, have remained elusive. This review will highlight the challenges that influenza viruses pose for rational vaccine design. In particular, it will consider the clinically beneficial endpoints, beyond complete sterilizing immunity, that have been achieved with vaccines against other infectious diseases, as well as the barriers to achieving similar success against influenza.
[h=4]KEYWORDS:[/h] effectiveness; efficacy; influenza; morbidity; mortality; transmission; vaccine
PMID: 30200179 DOI: 10.3390/vaccines6030058
Free full text
[h=1]The Future of Influenza Vaccines: A Historical and Clinical Perspective.[/h] Bouvier NM[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] For centuries, the development of vaccines to prevent infectious disease was an empirical process. From smallpox variolation in Song dynasty China, through the polysaccharide capsule vaccines developed in the 1970s, vaccines were made either from the pathogen itself, treated in some way to render it attenuated or non-infectious, or from a closely related non-pathogenic strain. In recent decades, new scientific knowledge and technologies have enabled rational vaccine design in a way that was unimaginable before. However, vaccines optimal against some infectious diseases, influenza among them, have remained elusive. This review will highlight the challenges that influenza viruses pose for rational vaccine design. In particular, it will consider the clinically beneficial endpoints, beyond complete sterilizing immunity, that have been achieved with vaccines against other infectious diseases, as well as the barriers to achieving similar success against influenza.
[h=4]KEYWORDS:[/h] effectiveness; efficacy; influenza; morbidity; mortality; transmission; vaccine
PMID: 30200179 DOI: 10.3390/vaccines6030058
Free full text